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Case presentation
A 13.5-year-old boy with relapsing nephrotic syndrome
was first treated for nephrosis at the age of 21 months. At
that time, clinical signs included facial edema, edema of
the extremities, and a distended abdomen. Blood pres-
sure and renal function were normal, but he had severe
hypoalbuminemia (1 g/100 ml), hypercholesterolemia,
and heavy proteinuria; 12-hour urine protein excretion
was 8.6 g. He was treated with a single 25 U dose of ad-
renocorticotropic hormone (ACTH), and prednisone was
administered in a divided dosage of 50 mg/day, for 2
weeks, and 60 mg, every other day, thereafter. Within I
week, urine protein excretion decreased to zero and ede-
ma remitted. The patient was discharged on a regimen of
penicillin prophylaxis and prednisone.
Over the next 8 months, the dosage of prednisone was
slowly tapered from 60 mg, every other day, to 10 mg,
every other day. Three to four days following onset of a
viral upper respiratory infection, however, proteinuria,
hypoalbuminemia, and edema recurred. The dosage of
prednisone was again increased to 60 mg, every other
day, and a clinical remission again resulted with qualita-
tive protein excretion decreasing to negative." Similar
relapses occurred at ages 3 and 4.5 years. During the lat-
ter episode, the proteinuria did not disappear for the 2
months during which prednisone was administered in a
75
dosage of 60 mg, every other day, but did subsequently
disappear following a 2-week regimen of 100 mg of pred-
nisone, every other day.
Six months later at age 5 years, proteinuria again re-
curred (24-hour urine protein excretion, 1.2 to 1.5 g) while
the patient was still receiving prednisone in a dosage of 50
mg, every other day. Azathioprine was administered for 2
weeks in a dosage of 50 mg/day but was stopped because
of an intercurrent episode of pneumonia. Over the next 6
months, proteinuria reappeared whenever the dosage of
prednisone was tapered to less than 30 mg, every other
day. Azathioprine was given for 3 months in a dosage of
50 mg/day, and prednisone was slowly tapered; one
month following institution of azathioprine therapy, the
24-hour urine protein excretion was 10 mg. Azathioprine
therapy was discontinued because mild leukopenia devel-
oped; prednisone was stopped as well, and the patient re-
ceived no medication for the next 3 months.
At age 6 years immediately following the onset of sys-
temic complaints related to a viral syndrome, the ne-
phrotic syndrome recurred (24-hour urine protein excre-
tion, 10.5 g). With no treatment, however, quantitative
protein excretion decreased within 2 weeks to 3.2 g and in
the following 3 weeks to undetectable levels. At age 7 years,
a partial relapse (24-hour urine protein excretion, 0.5 g)
prompted a brief course of prednisone therapy; the pa-
tient then remained in remission (24-hour urine protein
excretion, undetectable) for the next 1.5 years.
At age 8.5 years, heavy proteinuria reappeared. Ad-
ministration of prednisone in a dosage of 60 mg, every
other day, decreased 24-hour urine protein excretion to
33 mg within 2 weeks. The prednisone dose was tapered
and therapy was stopped after approximately 18 months.
One month later at age 10 years, 24-hour urine protein
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excretion increased again to 10 g. A 1-month course of
prednisone in a dosage of 60 mg, every other day, had no
effect nor did a second month of prednisone therapy at an
increased dosage of 120 mg, every other day; prednisone
therapy was therefore stopped. Eight months later at age
10.7 years, cyclophosphamide (75 mg/day) and predni-
sone (20 mg/day) were administered for 4 months. The
prednisone dosage was increased to 120 mg, every other
day, for the final 2 weeks of the therapeutic period and
then rapidly tapered. Twenty-four-hour urine protein ex-
cretion was 9.6 g before and 3.8 g following this regimen.
Over the 2 to 2.5 years since that last relapse and its
treatment with cyclophosphamide and prednisone, 24-
hour urine protein excretion has slowly decreased to its
most recent level of 130 mg. The patient's blood pressure
is normal, serum creatinine concentration is 0.7 mg, and
serum albumin concentration is 4.8 g/l00 ml. Growth and
development appear to be normal; the patient's height
and weight are just below the mean for his age.
Discussion
DR. WARREN E. GRUPE (Associate Professor of
Pediatrics, Harvard Medical School, Director of
Pediatric Nephrology, Children's Hospital): This
young man has experienced 12 years of steroid re-
sponsive, but relapsing, nephrotic syndrome,
treated at one time or another with ACTH, predni-
sone, azathioprine, and cyclophosphamide. In
some periods relapses were frequent and in others
infrequent; at times he was steroid dependent and at
other times he demonstrated spontaneous remis-
sions. The one surprise is that his long association
with an active university nephrology group did not
result in his having a renal biopsy.
The first question to answer is what particular va-
riety of nephrotic syndrome he has and whether a
renal biopsy is indeed necessary for that definition.
In this regard, we pediatricians have a distinct ad-
vantage over our internist colleagues. In the pediat-
nc age group, the overall frequency of the "minimal
change" lesion, or lipoid nephrosis, is 76% in un-
selected populations (see Table 1) [1—4]. Even in re-
ferral centers, this lesion is the most prevalent one,
occurring in about 45% of children with primary
nephrotic syndrome [2-3]. Moreover, children be-
low the age of 4 years have the highest prevalence
of lipoid nephrosis [4-6]. Thus, knowing only that
this child developed the disease at 21 months of age,
one can predict that he has the "minimal change"
lesion with about 90% accuracy [2, 6, 7].
Since the days of Munk [8], the absence of hema-
tuna, hypertension, or nitrogen retention have
pointed toward a diagnosis of lipoid nephrosis or
"minimal change" disease [9]. In recent years, a
normal concentration of the third component of ser-
um complement (C3) and highly selective proteinuria
have been added to the clinical signs characteristic
of minimal lesion nephrosis [2]. Of course, no single
clinical criterion is diagnostic. For example, 23% of
children with minimal change disease have micro-
scopic hematuria when first examined [2-4, 10]. In
fact, 52% of pediatric patients with the nephrotic
syndrome and hematuria have minimal change dis-
ease on biopsy, reflecting again the very high in-
cidence of this variant of nephrosis in this age group
[2-4, 10]. The diagnostic significance of nitrogen re-
tention or hypertension in children with nephrotic
syndrome is comparable to that described for hema-
tuna.
The selective proteinuria index, properly used,
can be quite helpful diagnostically [7, 11, 12]. The
proportion of patients with minimal change disease
who have highly selective proteinuria—that is,
those whose clearance of immunoglobulin G (IgG)
is less than 10% of the transferrin clearance—is 53
to 75% [2—4, 12]. However, 96% of nephrotic chil-
dren with a selective proteinuria index less than 0.1
Table I. Morphologic classification of primary nephrotic syndromea
Histology
Children
Adults
Unselected
patients
Referral
center
Minimal change (lipoid) nephrosis 76% 41% 23%
Membranoproliferative glomerulonephritis 8% 16% 7%
Focal and segmental glomerulosclerosis 7% 13% 12%t
Diffuse proliferative glomerulonephritis
Mesangial proliferative glomerulonephritis
2%
2% 8% 279°
Focal and global glomerulosclerosis 2% 5% t
Membranous glomerulonephropathy 2% 8% 28%
Unclassified or advanced chronic glornerulonephritis 1% 2% 3%
Infantile nephrotic syndromes <1% 3% -
a Data taken from Refs. 1-3.
Data often not separately categorized.
Relapsing nephrotic syndrome in childhood 77
have minimal change disease on biopsy [4, 12].
Thus, the finding of highly selective proteinuria is a
rather good predictor of morphology in children
even though the p:resence of "poorly" selective
proteinuria by no means excludes this diagnosis
(see Table 2). Parenthetically, neither does poorly
selective proteinuria preclude a response to steroid
therapy.
Certain clinical criteria when taken collectively
define with surprising accuracy a subgroup of chil-
dren who have a favorable outlook. The criteria for
inclusion in this favorable subgroup are (1) ages ito
10, (2) absence of nitrogen retention, (3) absence of
hematuria, (4) absence of hypertension, (5) normal
serum concentration of C3, and (6) highly selective
proteinuria; approximately 95% of such children
have minimal change disease on renal biopsy, re-
spond to steroid therapy, and have a good prognosis
[2, 7, i2]. Given the age of onset, the presenting
signs, the response to steroids, and the persistence
of normal renal function after 12 years of disease in
the patient described here, we can presume a diag-
nosis of minimal lesion nephrosis with an accuracy
that approaches that of renal biopsy. Thus, a biopsy
in the early stages of his disease could be consid-
ered unnecessary. In part, this analysis explains
why fewer pediatric patients are subject to renal
biopsy than are adults.
Assuming that this patient has a minimal change
lesion, let's turn to a review of our current under-
standing of the mechanisms of glomerular injury in
this particular histopathologic type of nephrosis. It
is fair to say that the pathogenesis remains totally
unknown [13]. Despite many attempts to implicate
humoral processes in the etiology, neither con-
vincing nor reproducible evidence exists. At one
time or another, various immunoglobulins were
considered important in the pathogenesis of this dis-
Table 2. Idiopathic nephrotic syndrome of childhood:
Relationship of selected clinical characteristics to complete
response to steroidsa
Clinical parameter Prevalence
Complete response
to steroids
if parameter
Present Absent
Hematuria (microscopic) 23% 33% 87%
Nitrogen retention 7.4% 33% 78%
Hypertension 8.1% 36% 78%SPI <0.l 56% 38% 97%
Serum C3 reduced 9.3% 0% 75%
a Data taken from Ref. 7.
SPI = selective proteinuria index.
order. The evidence, however, is not convincing.
Earlier reports of glomerular deposition of IgE have
not been confirmed consistently [14]. Nor is there
convincing indication that the reported alterations
in serum immunoglobulin concentrations—particu-
lary elevation of 1gM—follow a consistent pattern,
bear any specific relation to disease activity, or are
unique to minimal change disease [15, 16]. Besides,
it is difficult to interpret serum immunoglobulin con-
centrations in the presence of heavy proteinuria
without studies of synthesis and turnover. It seems
likely that alterations of immunoglobulin patterns
are only secondary manifestations of the disease.
Convincing evidence that the complement system
is involved is likewise lacking [13]. Early reports
suggested reduced concentrations of total hemo-
lytic complement (CH5O) in patients with lipoid
nephrosis" [17]. More recent reports in patients
with biopsy-proven minimal change disease, how-
ever, have failed to show abnormal concentrations
of CH5O [13]. Serum concentrations of C3 are
rarely, if ever, decreased [4, 7, 13] and C4 levels are
likewise normal [13]. Reports of reduced Ciq con-
centrations have not been confirmed [13]. Faint or
focal deposits of glomerular C3 have been reported
but are of doubtful significance. In fact, most neph-
ropathologists now include the absence of glomeru-
tar deposits by immunofluorescence in the morpho-
logic definition of minimal change disease.
It has been reported that immunoconglutinin be-
comes elevated in minimal change disease within 48
hours of a relapse and this finding has been thought
to have pathogenetic significance [18]. This eleva-
tion may be related to some other factors, however,
such as intercurrent infection. For example, one re-
port indentified 15 occasions in 30 patients in which
immunoconglutinin concentrations were raised; on
only two occasions was a high titer associated with
relapse [13].
The paucity of evidence supporting classical im-
munological mechanisms, coupled with the lack of
overt structural damage to the glomeruli, suggests
that some factor related to capillary permeability
could be responsible. This hypothesis would also be
consistent with the rapid appearance and reversal of
signs and symptoms of the disease, as well as the
variety of stimuli ranging from allergy to infection
that are associated with relapses. Evidence is begin-
ning to appear from several laboratories that such
circulating factors may indeed play a key role.
In one recent study, a factor was found in the
serum of 39 patients with steroid-responsive neph-
rotic syndrome that inhibited the agglutination of la-
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tex particles coated with human IgG [19]. Present
in relapse, this factor gradually disappeared with
successful steroid therapy. By Sepharose chroma-
tography, this factor contains "heavy" IgG; it has
been proposed that it represents a circulating im-
mune complex without complement activating ac-
tivity. Another study demonstrated that preformed
immune complexes, solubilized by exposure to ex-
cessive amounts of antigen and infused into saline-
loaded rats, produced oliguria and transient protein-
uria [20]. No complex deposition was demonstrated
in the glomeruli of these animals by immuno-
fluorescence. The authors suggested that such tran-
sient changes could be mediated by kinin activa-
tion, though no evidence for activation of this sys-
tem was presented. A factor has also been found in
the supernatants of cultured, stimulated lympho-
cytes from nephrotic patients in relapse that in-
creased vascular permeability in the guinea pig and
had kinin-like properties [21].
Recently, a lymphocytotoxic response toward
epithelial cells derived from trypsinized renal epi-
thelial cell cultures was demonstrated in 9 of 12 pa-
tients with minimal change disease [22]. The effect
in these patients was notably greater than that seen
in 12 patients with proliferative glomerulonephritis.
This difference was not thought to be attributable to
the phagocytic cells in the cellular preparations.
The relevance of these observations, however, is
not certain. For one thing, renal biopsies from pa-
tients with minimal change disease show little or no
evidence of epithelial cell damage from lympho-
cytes.
Using the leukocyte migration inhibition test in
eight patients with minimal change disease, Mallick
et al demonstrated what was considered to be T-cell
sensitization to an antigen obtained from a homoge-
nate of neonatal human kidney cortex [23]. A simi-
lar observation was made in other glomerular dis-
eases as well. In another group of patients with min-
imal change disease, 21 of 29 patients showed
evidence of lymphocyte sensitization to neonatal
kidney before receiving therapy for relapse as well
as during remission. Similar sensitization to adult
human kidney was not demonstrated, which raises
the question of whether these lymphocytes might be
responding to a persistent fetal antigen.
Some evidence suggests that T-cell function may
be suppressed in minimal change disease. Ooi was
able to demonstrate "cold" lymphocytotoxins in
the sera of five of eight patients with lipoid nephro-
sis and in six of ten patients with diffuse prolifera-
tive glomerulonephritis [24]. These lymphocytotox-
ins, thought to represent autoantibodies, have also
been described in systemic lupus erythematosus,
rheumatoid arthritis, pernicious anemia, allografted
animals, pregnant women, and aging populations;
however, they are not found in patients with other
renal lesions, such as acute tubular necrosis, renal
calculi, or polycystic disease. Therefore, a specific
relationship to minimal change disease, or for that
matter any proteinuric state, is in doubt. Another
study found that plasma from patients with minimal
lesion nephrosis in relapse inhibited autologous
lymphocyte responses to phytohemagglutin and al-
logenic lymphocytes [25]. This plasma factor was
not demonstrable in remission.
These several phenomena may reflect alterations
in T-cell function [26], but no evidence has clearly
established T-cell activity or suppression as a direct
mediator of altered glomerular permeability. These
studies do not yet follow a predictable pattern nor
yield a completely understandable role for the T-
cell in nephrotic syndrome [13]. Many of the phe-
nomena are not unique to minimal change disease
since some activity, suppression, or altered func-
tion is also detected in other forms of glomerular
disease or in diseases having no clear glomerular in-
volvement. The present evidence for T-cell in-
volvement in lipoid nephrosis is therefore sugges-
tive, exciting, and clearly worthy of further pursuit
even though currently somewhat incoherent.
The characteristic propensity for minimal change
disease to respond repeatedly to steroid therapy of-
fers no further insight into the nature of the gb-
merular injury. Despite the absence of prospective,
controlled studies, corticosteroids have become
fully accepted therapy for children with minimal
change disease [2—4, 10, 12]. Steroids have not,
however, been totally accepted for adults [27]. It is
not at all clear, however, how corticosteroids alter
the manifestations of the disease. These drugs are
called anti-inflammatory, yet there is no evidence of
glomerular inflammation in minimal change disease.
These drugs are likewise immunosuppressive, yet,
as discussed before, there is little evidence that im-
munoglobulins are in any way responsible for the
disease. There is no evidence for a direct steroid
effect on the glomerular basement membrane. It is
clear that corticosteroids affect lymphocytes; how-
ever, there is no indication that this is the mecha-
nism by which steroids reverse proteinuria.
Let us now turn to the therapeutic issues. Retro-
spective clinical studies suggest a beneficial long-
term effect of steroid therapy in children, and some
pediatric nephrologists believe that the improved
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survival rate in childhood is related to the better
control of the disease with steroid therapy [4, 12,
28]. Because of this widespread belief, it is difficult
to acquire data concerning the frequency of sponta-
neous remissions in children; from previous work
we suspect the rate is as high as 25% [28—30]. The
patient presented today did have a spontaneous re-
mission on at least one occasion.
Using prednisone dosages of 60 mg/M2/day in di-
vided doses, 85% of children with minimal change
disease become protein-free within 3 to 4 weeks
(see Table 3) [4, 7]. Eight percent require more than
4 weeks and 4V2% take as long as 12 weeks [4, 7]. In
this latter group, it is not clear that steroids actually
contribute to the response. Following an initial
clearing of proteinuria, several clinical courses are
possible. Fifteen to twenty percent of these children
require no further treatment and never have a re-
lapse of the disease; this is true despite the reintro-
duction in some cases of what might have been the
precipitating stimulus for that individual—for ex-
ample, infection or an allergic reaction [7, 30—33].
Eighty to eighty-five percent of children have sub-
sequent relapses, 55% having five or more relapses
of heavy proteinuria [7]. The frequency of relapse
tends to decrease as the child gets older [32]. Twen-
Initial Maintenance
ty-five to forty percent manifest steroid dependen-
cy—that is, proteinuria recurs whenever steroids
are discontinued [3, 4, 34, 35]; 3 to 10% eventually
become steroid resistant [7, 32].
This young man's course demonstrates the diffi-
culty of predicting the outcome for a given individ-
ual from group data. His initial response to steroids
was prompt and complete. He averaged one relapse
per year for the first 4 years of his disease, respond-
ing to medication given only every other day. Dur-
ing his third relapse he took a longer time to re-
spond; whether the remission would have been in-
duced more rapidly if he had been taking 60 mg/M2/
day in divided doses is uncertain. It has been the
experience of many pediatric nephrologists that a
higher proportion of patients respond to divided
daily doses than to the same amount of medication
given every other day.
At age 5, he developed what appears to have been
a steroid-dependent state, which was partially al-
tered coincident with short-term azathioprine thera-
py. The evidence that azathioprine is effective in
this disease is mixed. Several uncontrolled studies
using relatively large doses of the drug seemed to
indicate that it was efficacious [36—38]. In 1970—in
fact, shortly after this child was treated with
azathioprine—one controlled trial was reported in
which steroid-resistant patients were randomly allo-
cated to receive either intermittent prednisone ther-
apy plus azathioprine in a dosage of 60 mg/M2/day or
intermittent prednisone plus placebo for 90 days
[39]. Another group of frequently relapsing patients
was similarly allocated for 180 days of therapy [39],
This study failed to demonstrate an advantage of
adding azathioprine either in eliminating proteinuria
in nonresponsive patients or in altering the course
of patients with frequent relapses. As a result,
azathioprine is rarely used today in the management
of pediatric patients with relapsing nephrotic syn-
drome.
By contrast, in controlled studies the alkylating
agents cyclophosphamide and chlorambucil have
been clearly demonstrated to be effective in steroid-
dependent nephrotic syndrome [35, 40, 42]. In one
study, prednisone was given to all patients in a dos-
age of 60 mg/M2/day until proteinuria ceased, fol-
lowed by a similar dose given every other day for 4
months [40]. Cyclophosphamide in a dosage of 2.5
mg/kg/day was added to one group of such patients
but not to another group. During a follow-up period
of 14 to 39 months, over 90% of the patients treated
with prednisone alone experienced relapses, as
compared with only 17% of the patients treated with
Table 3. Therapy of minimal change nephrotic syndrome'
Prednisone
First attack I to 2 mg/kg/day or None
60 mg/M2/day
(maximum—80 mg/
day) in divided doses
until urine negative
for protein for 2
weeks
Relapse Ito 2 mg/kg/day or 3 mg/kg
60 mg/M2/day (maximum—80 mg)
(maximum—80 mg/ as single morning
day in divided doses dose every other
until urine negative day for 4 to 6 weeks
for protein for 2 more of a protein
weeks, negative urine, then
gradually reduce
dose over another 4
to 6 weeks until
discontinued 3
months after initial
therapy
Cyclophosphamide
2 to 3 mg/kg/day orally, together with steroids, for 8 to 10 weeks
maximum
Chlorambucil
0.2 to 0.3 mg/kg/day orally, together with steroids, for 10 to 12
weeks maximum
a Data taken from Ref. 10.
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both drugs. Another study compared the same total
dose of cyclophosphamide given over two periods
of time [35]. One group received cyclophosphamide
in a dosage of 2.5 mg/kg/day for 90 days, while a
second group received 5 mg/kg/day for 45 days.
Prednisone was given throughout the period of cy-
clophosphamide therapy. The duration of remission
induced was similar in both groups. The frequency
of acute toxic side effects, however, was signifi-
cantly higher in the group receiving the larger daily
dose of cyclophosphamide. It also should be noted
that cyclophosphamide, given together with ster-
oids, will occasionally convert an initially steroid-
unresponsive patient to steroid responsive.
It is clear that the development of leukopenia or
other toxicity is not required to achieve a therapeu-
tic response from cyclophosphamide; moreover,
the duration of the subsequent remission does not
depend on producing marrow suppression. There is
some evidence, however, that the duration of re-
mission following a course of therapy may be re-
lated to the duration of therapy [41]. In patients
treated for less than 6 weeks, as few as 27%remain
in remission beyond the first year. Currently the
usual course of therapy consists of cyclophospha-
mide and prednisone given for 2 months. With this
regimen, one can expect a remission rate of 58% at
2 years and 44% at 4 years [41]. If treatment is ex-
tended to 3 months, about two-thirds of patients
will be in remission 5 years or more after therapy
[41]. As noted in the case report, the patient was
treated in this manner for 4 months and in fact is in
remission 2.5 years later.
There is only one report of a prospective, con-
trolled study using chlorambucil [42]. In this study,
21 children with either steroid-dependent or fre-
quently relapsing nephrotic syndrome were exam-
ined. All control patients treated with prednisone
alone continued the same pattern and rate of re-
lapse; in all such patients, proteinuria returned by 7
months. The group which received prednisone
along with chiorambucil for 6 to 12 weeks remained
in complete remission without further medication
during the 12 to 34 months of observation. A com-
parison with published reports of cyclophospha-
mide suggested that the remission induced by chlo-
rambucil was more "stable." A subsequent study
showed that 84% of children so treated were in re-
mission 3 years later and 78% at 5 years [43]. Fur-
ther evaluation shows that a total chlorambucil dose
in excess of 14 mg/kg or daily doses in excess of 0.3
mg/kg for treatment periods in excess of 12 weeks
confer no additional benefit and thus are no longer
warranted [43, 44]. As in the case of cyclophospha-
mide, there is no evidence that leukopenia is neces-
sary to attain a therapeutic effect. One of the appar-
ent advantages of chlorambucil has been its minimal
immediate toxicity when compared with cyclophos-
phamide. It may be, however, that this low immedi-
ate toxicity is a major disadvantage because it per-
mits the use of doses far in excess of those needed
to alter the course of the disease. Current recom-
mendations are to limit the daily dose of chlorambu-
cil to 0.2 mg/kg and to continue therapy for no more
than 10 to 12 weeks. Even this dosage may be more
than necessary.
Acute and chronic toxicity remain a major con-
cern with cytotoxic agents [10, 42, 45]. Toxicity in-
cludes marrow depression, infection, alopecia, nau-
sea and vomiting, tumor induction, chemical cys-
titis, hepatitis, phlebitis, oral ulceration, and
sterility. Alopecia and chemical cystitis are much
more common with cyclophosphamide than with
chlorambucil. Both appear to be dose related, but
with currently recommended dosage schedules
these complications should not be a major problem.
Bladder fibrosis may develop in patients treated
with cyclophosphamide, but has usually been a
problem with high doses used over time periods
longer than that necessary to achieve an effect in
minimal change disease. Gastrointestinal irritation
is generally minor and has not seriously limited the
use of either of these drugs. We have seen no ex-
amples of hepatitis, phlebitis, or oral ulceration at
the doses we have outlined.
Sterility has been reported in both sexes with cy-
clophosphamide [41, 46]. The male appears to be
more at risk than the female, and the effect seems to
be related to both dose and the duration of treat-
ment. Doses below 5 mg/kg/day for less than 60
days do not seem to produce azoospermia, while
similar doses for longer than 89 days are routinely
followed by this complication [46]. The threshold
for cyclophosphamide-induced azoospermia seems
to be a cumulative dose above 250 mg/kg or ex-
posure for greater than 60 days [46]. With chlo-
rambucil, azoospermia occurs in both prepubertal
and pubertal males with cumulative doses in excess
of 7 mg/kg when given without steroids or at greater
than 17 mg/kg when given with steroids [47, 48]. At
a cumulative dose in excess of 25 mg/kg, azoo-
spermia is virtually certain to occur [48]. Recovery
of spermatogenesis has been reported after discon-
tinuing the drugs in both cases [49, 50].
Malignant tumors rarely develop after therapy
with both drugs. Solid tumors complicate therapy
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with cyclophosphamide, and leukemia complicates
therapy with chlorambucil; these malignancies usu-
ally appear within 3 years of drug therapy [51]. Four
cases of leukemia have been reported in children
following treatment with chlorambucil [52]. Three
of the four patients also received other cytotoxic
drugs, and all were treated with either higher doses
or for longer durations than that which we currently
recommend. We have followed 35 children for long-
er than 3 years and fortunately none has developed
a malignancy [43].
Focal seizures occur in about 6% of children
treated with chlorambucil [53]. These seizures are
transient and unrelated to age, underlying disease,
duration of illness, dose, or duration of therapy.
The multiple serious complications of therapy
with alkylating agents make it critically important to
establish the lowest minimum effective dose for
both medications and mandate careful selection of
patients to receive this therapy. We restrict the use
of these drugs to children with established steroid
dependence or resistance, who are experiencing the
severe side effects of corticosteroid therapy; often
such patients fail to grow and are debilitated by the
combined effects of steroid treatment and the per-
sistent protein-losing state [42]. We do not use these
medications in children for whom steroids have be-
come only a nuisance. With current selection cri-
teria, I doubt that we would have selected this pa-
tient for treatment with alkylating agents.
In contrast to steroids, it is clear that these drugs
alter the course of minimal change nephrosis in
childhood [10], but as just noted, the complications
of therapy with cytoxic agents are worrisome. For
this reason some investigators have sought to alter
steroid regimens to achieve a better therapeutic ef-
fect with less toxicity. In one ongoing study in chil-
dren with frequent relapses, the Mid-European Ste-
roid Trial, intermittent steroid therapy was com-
pared with alternate day steroid therapy [54].
Progress reports from this study indicate that alter-
nate day prednisone in a dosage of 35 mg/M2!48
hours is more effective than intermittent prednisone
in a dosage of 40 mg/M2, for 3 out of every 7 days, in
reducing the relapse rates [54]. The children return
to their familiar pattern of frequent relapses, how-
ever, when treatment is stopped. Thus, one may be
able to suppress relapses with long term alternate
day therapy, but this effect does not appear to alter
the course of the disease.
Another approach to this problem has come from
Helsinki. Using the 2-hour ACTH-stimulated corti-
sol level as a probe, this group has shown that chil-
dren with long remissions had significantly higher
plasma cortisol responses both before and after
prednisone therapy than children with frequent re-
lapses [55, 56]. A normal response to ACTH pre-
dicted a remission of 6 months or longer, whereas a
subnormal response predicted a relapse within a 6-
month period. These results imply that patients
with frequent relapses have a suppression of the hy-
pothalamic-pituitary-adrenal (HPA) axis and sug-
gest that this suppression, possibly induced by ste-
roid therapy, may promote a relapse. There is no
indication yet, however, that allowing the HPA axis
to return to normal has any effect on the course of
the disease or the frequency of relapses.
What does the future hold for this young man?
His protein excretion is only slightly increased for
his age and size, he has normal renal function, and
he is growing and developing normally. He may re-
main symptom-free for many years, develop occa-
sional relapses, or indeed develop frequent relapses
once more. Should this be the case, a second course
of cyclophosphamide or chlorambucil could be con-
sidered. Over the long term, however, we must
keep things in perspective; although the mortality
for all nephrotic children is 7 to 12% [10], while the
mortality for children with minimal lesion, steroid-
responsive disease, as this boy has, should not ex-
ceed 1 to 2% [7, 10].
In closing, we might keep our therapeutic reli-
gions also in perspective by reviewing one more
study. This report describes a follow-up study of 26
children who had the nephrotic syndrome for 2 to 5
years or more [28]. Although 27% died, only 15%
had persistent proteinuria and 50% recovered com-
pletely with no evidence of the disease. The date of
the report—1929; the form of treatment—kidney
decapsulation.
Questions and Answers
DR. J. T. HARRINGTON: Dr. Grupe, I should like
to make two comments and then ask a question.
First, for the reasons you mentioned at the outset of
the discussion, I chose not to perform a renal
biopsy in this patient but simply assumed that he
had minimal change disease. Second, with the ex-
ception of the first 2 weeks, I chose not to use daily
steroid therapy in this child because of my concern
about the side effects of prednisone. My question is,
have any studies demonstrated measurable differ-
ences in the incidence of side effects in pediatric pa-
tients treated either with daily or every other day
therapy?
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DR. W. E. GRUPE: I am unaware of a published
study that prospectively compares the various ste-
roid programs in that manner. No one of the many
treatment programs in the literature that vary in
dosage, duration of initial therapy, and use of main-
tenance therapy has emerged as clearly superior in
either short or long-term results [10]. The published
studies using alternate day steroids as initial treat-
ment claimed it was as effective in producing a com-
plete remission as daily therapy but with less tox-
icity [57, 58]. These were studies in a heterogeneous
group of unbiopsied patients, however, and long-
term outcome was not included. Other pediatric
nephrologists found alternate day steroids to be su-
perior maintenance therapy but not as effective as
initial treatment. The practice failed to gain wide ac-
ceptance in pediatrics.
The patients with frequent relapses or steroid de-
pendency are a major concern since they are at
greater risk for more steroid toxicity, and in children
for more growth problems. Early studies in Belgium
suggested these patients might have emerged be-
cause of steroid therapy [59]. Steroid schedules
with less suppressive effect may need to be devised
for even the initial episode. This is what is implied
in the Finnish studies that relate frequent relapses
to suppression of the HPA axis [55, 56].
DR. BORIS SENIOR (Chief, Pediatric Endocrinolo-
gy, New England Medical Center Hospital): Have
you had any experience with the use of methyl-
prednisolone intravenously?
DR. W. E. GRUPE: No we have not. There is a
very preliminary indication, however, that methyl-
prednisolone administered intravenously is as ef-
fective as prednisone taken orally for the induction
of a remission [60]. Whether the subsequent course
of the disorder will prove to be any different re-
mains to be seen.
DR. B. SENIOR: Do you think parenteral methyl-
prednisolone provides any advantages in the patient
who has not responded to daily prednisone in an
adequate dose?
DR. W. E. GRUPE: I don't believe there are suf-
ficient data to indicate that methylprednisolone ad-
ministered intravenously is any more effective than
steroids taken orally in the nonresponsive patient
with minimal change disease.
DR. DAVID BUSHINSKY tRenal Fellow, New Eng-
land Medical Center Hospital): Given the poten-
tially serious complications of treatment, the pauci-
ty of evidence that therapy alters the natural history
of the disease, and our capacity to treat the disease
symptomatically with diuretics, are we in fact justi-
fled in treating these young patients with steroids,
let alone the cytotoxic agents you described?
DR. W. E. GRUPE: That is a very good point, and
it is really at the crux of the conceptual difference
between adult and pediatric patients. In children,
we are concerned with growth and development
and think of survival in terms of many decades.
Even though the adult with minimal change disease
may respond as readily as a child to steroid therapy
[27], there are many whose edema can be controlled
with diuretics alone; it is my impression that control
of edema with diuretics alone is more difficult to
achieve in the child. In addition, diuretic therapy
does not control the proteinuria, hypoproteinemia,
and hyperlipidemia. The child with massive protein-
uria and hypoproteinemia does not grow. Finally,
the long-term effects of prolonged diuretic therapy
are not really known in such children, particularly
in terms of growth and development.
If we return to the presteroid, preantibiotic peri-
od, only one-third of these patients survived the
first 5 years [28, 30]. After the introduction of anti-
biotics, survival doubled [28, 30]. With the current
control of the disease with steroids, plus better anti-
biotics and more potent diuretics, death at 5 years is
now only 1.5 to 6% [10]. Whether that could be
achieved in children with diuretics and antibiotics
alone is not known, and I know of no one who really
wants to withhold steroids to find out.
I would insert another caution about diuretic
therapy. High doses of potent diuretics in a severely
hypovolemic child may produce more contraction
of the plasma volume without necessarily producing
a significant change in plasma oncotic pressure or a
shift of extracellular fluid to the plasma space. Our
concern is that either venous or arterial thrombosis
could be enhanced by volume contraction in these
patients.
Even if we accept steroid therapy as reasonable,
there seems to be no long-term advantage to using
high doses for prolonged periods. I would hope we
would all examine steroid therapy more carefully.
DR. J. P. KASSIRER: I have the same concerns
about therapy with cytotoxic drugs per se, and I
was about to ask a similar question. I have resisted
giving children with steroid-dependent nephrotic
syndrome anything but steroids, particularly out of
concern for their becoming sterile. I haven't felt
that this cost was worth the marginal benefit. How
do you select patients for therapy with these
agents?
DR. W. E. GRUPE: I agree that cytotoxic drugs
should be used with caution. We restrict their use to
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patients for whom continued use of steroids is es-
sential, but they are becoming a real danger [42, 53].
Many patients with steroid dependency or frequent
relapses can be maintained on low dose alternate
day steroid therapy in complete remission with nor-
mal growth and development. A smaller subgroup,
however, requires higher doses or more frequent
daily therapy resulting in serious steroid toxicity
and growth arrest. It is this high-risk problem group
that we have included in our chlorambucil program
[42].
DR. J. T. HARRINGTON: I should like to comment
briefly on some of the reasons we treated this pa-
tient on so many occasions. I believe there are often
a number of psychosocial reasons beyond protein-
uria that may make it reasonable to use cytotoxic
drugs in appropriate doses. For instance, when this
patient relapsed and became severely edematous,
he was reluctant to go to school because the other
children made fun of him. In addition, he was a very
good hockey player and when he relapsed during
the hockey season he became so edematous that he
could not play, which was very detrimental to his
morale and general well-being.
DR. LAWRENCE FEINGOLD (St. Luke's Hospital,
New Bedford, Massachusetts): How long do you
wait after a child relapses for spontaneous remis-
sion to occur? Do you treat soon after a relapse?
DR. W. E. GRUPE: We generally allow 10 days to
2 weeks of proteinuria before restarting steroids,
particularly when the relapse was initiated by an in-
tercurrent infection. I am not sure that we wait long
enough; maybe spontaneous remissions would be
more frequent if we allowed a longer interval. Our
aim, however, is to avoid edema and hospital-
ization.
DR. J. J. COHEN: I wonder if you would elaborate
further about the pathogenesis of this fascinating
condition. Histologically, there appears to be no
evidence for an immunologic basis, yet the only
common denominator linking the two classes of ef-
fective therapeutic agents, namely steroids and
cytotoxic drugs, is that they are immunosup-
pressive.
DR. W. E. GRUPE: They are indeed immuno-
suppressive, but they can affect other cells as well.
It is conceivable that they impede the function of a
group of cells producing a factor that alters gb-
merular permeability in a nonimmunologic way.
DR. J. J. COHEN: Would that relate in any way to
the observation that infections often seem to precip-
itate a relapse of proteinuria in this condition?
DR. W. E. GRUPE: There is not an all inclusive or
cohesive hypothesis as yet. Infections, like allergy,
bee stings, or poison ivy, may be a nonspecific stim-
ulus to whatever it is that alters glomerular per-
meability.
DR. J. J. COHEN: One of the most exciting new
concepts about gbomerular function, as everyone is
aware, is the influence of electrical charge on the
permeability of macromolecules. This raises the ob-
vious possibility that this disease is the result of
some alteration in the fixed negative charges. Is
there any evidence that this might be the case?
DR. W. E. GRUPE: The negatively charged gly-
cocalyx covering the epithelial cell is one of four
potential barriers to protein molecules in the gb-
merular capillary wall. The other three are the
endothelial cell, the basement membrane, and the
epithelial slit diaphragm. In the experimental ani-
mal, neutralization of the negative charge with pro-
tamine produces a reversible spreading and fusion
of the foot processes and an increase in proteinuria
[61, 62]. Obviously, this is very similar to that seen
in a variety of proteinuric states and suggests that
such an electrical barrier is important to the perm-
selectivity of the glornerular capillary wall.
It is not clear whether changes in the glycocalyx
are primary or secondary, however. Like the slit di-
aphragm, the glycocalyx is on the wrong side of the
barrier to be the effective primary filter [63]. Like-
wise, preliminary studies in early autobogous im-
mune complex nephritis in rats have shown a loss of
colloidal iron staining subjacent to very small sub-
epithelial deposits before an increase in protein ex-
cretion could be demonstrated [64]. Other studies
also suggest that changes elsewhere in the capillary
wall are primary while the loss of intrinsic negative
charge is contributory [65]. Of further interest, it
appears that the two lamina rarae are also rich in
polyanionic radicals [66].
As might be expected, a decrease in glomerular
glycocalyx staining has been seen in human lipoid
nephrosis concomitant with proteinuria [67]. It is
still possible, however, that a primary change in the
basement membrane has allowed increased per-
meability, which has then led to alterations on the
epithelial side, including loss of the glycocalyx,
curling and wrinkling of the slit diaphragm, and
podocyte fusion.
DR. J. J. COHEN: Are there any therapeutic ma-
neuvers available to alter glomerular charge?
DR. W. E. GRUPE: Not to my knowledge, unless
that is what prednisone does.
DR. KENNETH SHAPIRO (Renal Fellow, New
England Medical Center Hospital): Dr. Grupe, you
noted that in the group of patients who didn't re-
spond to prednisone there was a high mortality.
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Have those patients been biopsied, and if so, what
is the most common lesion found in that group of
youngsters?
DR. W. E. GRUPE: The two most common steroid
resistant lesions in children are focal segmental
sclerosis and membranoproliferative glomerulone-
phritis (see Table 1). In children, these are also the
most frequent reasons for progression to renal in-
sufficiency. In the adult, the most common lesion, I
believe, is extramembranous glomerulonephropa-
thy.
DR. J. T. HARRINGTON: It was my understanding
that even children whose nephrotic syndrome ulti-
mately becomes steroid-resistant still have a greater
chance of having minimal change disease than any
other pathologic entity given the very high a priori
probability of minimal change disease in children.
DR. W. E. GRUPE: I would agree with that, but I
would caution that any biopsy diagnosis of minimal
change disease is not an absolute. It is not that un-
usual for a focal lesion to be missed [68]; even serial
sections of the tissue may fail to disclose a lesion,
particularly if the biopsy is superficial. I am skepti-
cal of morphologic diagnoses based solely on light
microscopy. I think a good number of patients with
"biopsy proven" minimal change disease with ei-
ther steroid resistance or progression to renal fail-
ure represent other morphologic variants hidden in
an inadequate biopsy [10].
Reprint requests to Dr. Warren E. Grupe, Division of Nephrol-
ogy, Children's Hospital Medical Center, 300 Longwood Ave-
nue, Boston, Massachusetts 02115.
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